Clinical Edge Journal Scan Commentary

Clinical Edge Journal Scan

Commentary: Newer Drugs for AD Plus Dupilumab and Other Issues, September 2023

Author:: Steven R. Feldman, MD, PhD

Publish date: August 24, 2023

Read More

Clinical Edge Journal Scan

Commentary: Abrocitinib, Malignancy Risk, and S aureus in AD, August 2023

Author:: Steven R. Feldman, MD, PhD

Publish date: July 31, 2023

Read More

Clinical Edge Journal Scan

Commentary: Topical treatments, dupilumab, and long-term treatment of AD, July 2023

Author:: Steven R. Feldman, MD, PhD

Publish date: June 22, 2023

Read More

Clinical Edge Journal Scan

Commentary: Topical treatments, dupilumab, and long-term treatment of AD, July 2023

Author:: Steven R. Feldman, MD, PhD

Publish date: June 22, 2023

Read More

Clinical Edge Journal Scan

Commentary: AD, RA, Probiotics, and a New JAK inhibitor, June 2023

Author:: Steven R. Feldman, MD, PhD

Publish date: May 30, 2023

Read More

Clinical Edge Journal Scan

Commentary: Three New AD Treatments and a Study of Food Allergy, May 2023

Author:: Steven R. Feldman, MD, PhD

Publish date: April 26, 2023

Read More

Clinical Edge Journal Scan

Commentary: IL-31 inhibitor, e-cigarettes, and upadacitinib in AD, April 2023

Author:: Steven R. Feldman, MD, PhD

Publish date: March 29, 2023

Read More

Clinical Edge Journal Scan

Commentary: Sorting out useful atopic dermatitis research from filler, March 2023

Author:: Steven R. Feldman, MD, PhD

Publish date: March 1, 2023

Read More

Clinical Edge Journal Scan

Commentary: A New Drug, and Pediatric Concerns, February 2023

Author:: Steven R. Feldman, MD, PhD

Publish date: January 27, 2023

Read More

Clinical Edge Journal Scan

Commentary: Evaluating Recent Drug Developments in Atopic Dermatitis, January 2023

Author:: Steven R. Feldman, MD, PhD

Publish date: December 29, 2022

Read More

Clinical Edge Journal Scan

Commentary: Prevention in AD, December 2022

Author:: Jonathan Silverberg, MD, PhD, MPH

Publish date: December 7, 2022

Read More

Pages